Русский
Anticoagulants In Cardiology: Prospects For New Drugs
E.Yu. Vasilyeva, I.I. Vorobjeva
Anticoagulants in cardiology: prospects for new drugs
Numerous difficulties in the unfractionated heparin and warfarin administration have stimulated the search for new direct anticoagulants. Some groups of new drugs with several advantages, predominantly with lower risk of bleeding, are appeared. First of all this applies to the low molecular weight heparins, fondaparinux and bivalirudin. In addition, the last two drugs in contrast to heparin do not cause platelet activation and thrombocytopenia. They already take place in the European and American recommendations for the treatment of acute myocardial infarction (with or without ST segment elevation) and pulmonary embolism. Research for new anticoagulants continues. Currently clinical trials of oral forms of factor Xa inhibitor (rivaroksaban), direct thrombin inhibitors (dabigatran), and the new vitamin K antagonists (ATI-5923) are in progress, and investigators examine them use in patients with atrial fibrillation.
Numerous difficulties in the unfractionated heparin and warfarin administration have stimulated the search for new direct anticoagulants. Some groups of new drugs with several advantages, predominantly with lower risk of bleeding, are appeared. First of all this applies to the low molecular weight heparins, fondaparinux and bivalirudin. In addition, the last two drugs in contrast to heparin do not cause platelet activation and thrombocytopenia. They already take place in the European and American recommendations for the treatment of acute myocardial infarction (with or without ST segment elevation) and pulmonary embolism. Research for new anticoagulants continues. Currently clinical trials of oral forms of factor Xa inhibitor (rivaroksaban), direct thrombin inhibitors (dabigatran), and the new vitamin K antagonists (ATI-5923) are in progress, and investigators examine them use in patients with atrial fibrillation.
